Core Insights - Longeviti Neuro Solutions has appointed Tim Scannell, former President & COO of Stryker Corporation, as Chair of its Board of Directors, aiming to enhance its strategic direction in neurotechnology [1][6] - The company has established a $10 million strategic capital partnership with Soleus Capital to support hiring, product development, and medical education initiatives [1][5] Company Overview - Longeviti Neuro Solutions focuses on innovative platform solutions for complex brain disorders, with a mission to improve patient care during and after surgery [8][9] - The company has full in-house capabilities for manufacturing, packaging, designing, and sterilizing, along with multiple FDA clearances and ISO 13485 Certifications [8] - Longeviti's products are approved for use in over 120 hospitals globally and have assisted over 4,000 patients to date [9] Leadership and Strategic Direction - Tim Scannell brings over thirty years of experience in the medical device market, having held various leadership roles at Stryker Corporation, including Group President of MedSurg & Neurotechnology [2][4] - As Chair, Scannell will help formulate strategic plans and provide oversight, leveraging his extensive experience in scaling MedTech businesses [4][6] - Scannell expressed confidence in Longeviti's leadership and technology, emphasizing the potential for significant advancements in patient care within the neuro industry [7] Investment Partnership - Soleus Capital, a healthcare investment firm with approximately $2 billion in assets under management, has committed $10 million in structured financing to Longeviti [10] - The partnership aims to enable Longeviti to scale its team, enhance its market presence, and amplify its impact on patients with complex brain disorders [5][7]